Recent updates to Ph. Eur. 2.6.7 and USP <77> place greater emphasis on full-workflow validation, control strategies, sensitivity justification, and fit-for-purpose implementation of nucleic acid testing (NAT) methods. The focus is shifting from simple method comparison toward demonstrating reliable, reproducible performance across the entire mycoplasma testing workflow. Pharmacopeial Mycoplasma testing expectations haven’t suddenly changed overnight—but they have shifted in meaningful ways.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with MinGin
Contact MinGin, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack